View from Stars and Stripes life guard hut on Miami Beach
Our latest article is part Journal Club entry for August, part look back at some data from AACR and ASCO plus a part look at a relatively new target from an obscure biotech that caught my attention recently.
To do this, we pose three critical questions and attempt to answer them.
The targets and markers chosen for review here may well surprise a few people.
If we want to understand how to help more people respond to cancer immunotherapy then we need o understand the underlying biology and the tumour microenvironment in greater depth than we currently do.
Gradually, we are getting more clarity on a few areas as new data is being published…
To learn more from our latest review of data as well as companies and targets to get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This week I was fascinated (but not surprised) to learn an interesting snippet from an article in Forbes on Hal Barron and GSK by Matthew Herper. Herper wrote:
“David Schenkein, the chief executive of Agios Pharmaceuticals, worked for Barron at Genentech. He says he’s never worked with anyone who read more of the original scientific literature on a topic before making a decision.”
This should be a given yet… not everyone does that. Dr Scheinkein (whom we interviewed here) is no slouch either, so that’s quite a compliment. By the way, for an alternative take on the R&D update, check out John Carroll’s article on Endpoints.
Revvin’ up our understanding of the immune system
It is, however, good to see some CMOs and CSOs reading extensively in the literature themselves rather than relying on summaries from project teams, although I highly recommend they should because it’s a great way to keep the brain revved up with new developments and also understand the field more intimately.
This is also one reason why we have regular Journal Club posts on BSB – to highlight important new developments that are worthy of attention and explain why they matter.
It is encouraging that quite a few of our subscribers are c-suite execs, including CEOs, CMOs, and CSOs who often send in links to papers they are curious for an independent perspective on.
It’s time for the latest look at some key research that may have practical impacts in numerous ways…
To learn more from our latest thought leader interview and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
The audience of Biotech Strategy Blog is a broad “church” (no pun intended) of professionals associated with cancer drug development.
Bridge of Sighs, Oxford
Some readers with a research focus noticed I was in Oxford recently then contacted me to ask what scientific papers I was reading and catching up on over the lazy summer months?
This got me thinking as I was vividly reminded of my days as a PhD student at King’s College London, where the department would regularly meet to discuss key papers and recent research.
If your work has a narrow focus, and that applies to industry too, it’s sometimes difficult to see what’s on the horizon or be stimulated by ideas outside your immediate field, yet cross-fertilisation is an important pillar of learning. That’s one of the advantages of BSB, we cover a wide range of topics, at varying levels of complexity.
Welcome to the BSB Journal Club!
In this inaugural post, I’ve selected several recently published cancer immunotherapy papers that caught my attention, also a couple of books for your summer reading.
In case you worry that the science is above your ‘pay grade,’ for each I’ve written a brief summary and highlighted what data means from a commercial/new product development persepctive. You are of course most welcome to agree/disagree and reach your own conclusions… I hope it will stimulate your thinking.
Science often moves forward and develops as people make connections from a broader perspective. I’m planning on running the “Journal Club” as a monthly ad hoc post to dovetail with the Reader Q&A Mailbag.
Subscribers can login or you can purchase access.